Skip to main content

Barclays Downgrades Amag Pharmaceuticals After 130% Rally From Lows

Barclays analyst Balaji Prasad downgraded Amag Pharmaceuticals to Equal Weight from Overweight with an unchanged price target of $10.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.